KPTIQ — Karyopharm Therapeutics Share Price
Last trade - 00:00- $0.39m
- $257.57m
- $146.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -98.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 209.82 | 157.07 | 146.03 | 145.24 | 146.07 | 134.39 | 159.89 | 6.21% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Directors
- Barry Greene LED (62)
- Deepika Pakianathan IND (61)
- Garen Bohlin IND (78)
- Richard Paulson PRE (58)
- Christy Oliger IND (56)
- Chen Schor IND (53)
- Michael Mano SVP (49)
- Sohanya Cheng EVP (43)
- Stuart Poulton EVP (53)
- Reshma Rangwala EVP (48)
- Lori Macomber CFO (55)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- December 22nd, 2008
- Public Since
- November 6th, 2013
- No. of Shareholders
- 16
- No. of Employees
- 228
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 22,681,460
- Address
- 85 Wells Avenue, Second Floor, NEWTON, 02459
- Web
- https://karyopharm.com
- Phone
- +1 3026587581
- Auditors
- Ernst & Young LLP
Latest News for KPTIQ
Upcoming Events for KPTIQ
Q3 2026 Karyopharm Therapeutics Inc Earnings Release
Q4 2026 Karyopharm Therapeutics Inc Earnings Release
Similar to KPTIQ
Acusphere
Pink Sheets on Nasdaq
Adaptimmune Therapeutics
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
Allied
Pink Sheets on Nasdaq
FAQ
As of Today at 11:33 UTC, shares in Karyopharm Therapeutics are trading at $0.03. This share price information is delayed by 15 minutes.
Shares in Karyopharm Therapeutics last closed at $0.03 and the price had moved by -99.54% over the past 365 days. In terms of relative price strength the Karyopharm Therapeutics share price has underperformed the S&P500 Index by -99.59% over the past year.
The overall consensus recommendation for Karyopharm Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreKaryopharm Therapeutics does not currently pay a dividend.
Karyopharm Therapeutics does not currently pay a dividend.
Karyopharm Therapeutics does not currently pay a dividend.
To buy shares in Karyopharm Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.03, shares in Karyopharm Therapeutics had a market capitalisation of $0.39m.
Here are the trading details for Karyopharm Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: KPTIQ
Based on an overall assessment of its quality, value and momentum Karyopharm Therapeutics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Karyopharm Therapeutics is $10.22. That is 40129.89% above the last closing price of $0.03.
Analysts covering Karyopharm Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.89 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Karyopharm Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -99.67%.
As of the last closing price of $0.03, shares in Karyopharm Therapeutics were trading -99.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Karyopharm Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Karyopharm Therapeutics' management team is headed by:
- Barry Greene - LED
- Deepika Pakianathan - IND
- Garen Bohlin - IND
- Richard Paulson - PRE
- Christy Oliger - IND
- Chen Schor - IND
- Michael Mano - SVP
- Sohanya Cheng - EVP
- Stuart Poulton - EVP
- Reshma Rangwala - EVP
- Lori Macomber - CFO